Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 604

1.

Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.

Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, Huland H, Tilki D.

Eur Urol. 2019 Feb 13. pii: S0302-2838(19)30094-6. doi: 10.1016/j.eururo.2019.01.048. [Epub ahead of print]

PMID:
30772034
2.

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment.

Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H.

World J Urol. 2019 Feb 6. doi: 10.1007/s00345-019-02668-z. [Epub ahead of print]

PMID:
30725166
3.

Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records.

Leyh-Bannurah SR, Tian Z, Karakiewicz PI, Wolffgang U, Sauter G, Fisch M, Pehrke D, Huland H, Graefen M, Budäus L.

JCO Clin Cancer Inform. 2018 Dec;2:1-9. doi: 10.1200/CCI.18.00080.

4.

The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy.

Pompe RS, Krüger A, Preisser F, Karakiewicz PI, Michl U, Graefen M, Huland H, Tilki D.

Eur Urol Focus. 2018 Dec 31. pii: S2405-4569(18)30410-3. doi: 10.1016/j.euf.2018.12.008. [Epub ahead of print]

PMID:
30606686
5.

Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study.

Preisser F, Mazzone E, Nazzani S, Knipper S, Tian Z, Mandel P, Pompe R, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2018 Dec 26. pii: S2405-4569(18)30405-X. doi: 10.1016/j.euf.2018.12.006. [Epub ahead of print]

PMID:
30594487
6.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
7.

Upregulation of centromere protein F is linked to aggressive prostate cancers.

Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, Sauter G, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Luebke AM.

Cancer Manag Res. 2018 Nov 9;10:5491-5504. doi: 10.2147/CMAR.S165630. eCollection 2018.

8.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer.

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis MC, Lübke AM, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R.

Cancer Manag Res. 2018 Nov 19;10:5909-5917. doi: 10.2147/CMAR.S172637. eCollection 2018.

9.

Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer.

Lange T, Oh-Hohenhorst SJ, Joosse SA, Pantel K, Hahn O, Gosau T, Dyshlovoy SA, Wellbrock J, Feldhaus S, Maar H, Gehrcke R, Kluth M, Simon R, Schlomm T, Huland H, Schumacher U.

Sci Rep. 2018 Dec 3;8(1):17535. doi: 10.1038/s41598-018-35695-8.

10.

Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes.

Leyh-Bannurah SR, Zaffuto E, Dell'Oglio P, Tian Z, Moschini M, Capitanio U, Briganti A, Montorsi F, Fisch M, Chun F, Kachanov M, Budäus L, Graefen M, Huland H, Karakiewicz PI.

Urol Int. 2019;102(1):51-59. doi: 10.1159/000495071. Epub 2018 Nov 27.

PMID:
30481764
11.

Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.

Tilki D, Chen MH, Wu J, Huland H, Graefen M, Braccioforte M, Moran BJ, D'Amico AV.

JAMA Oncol. 2018 Nov 15. doi: 10.1001/jamaoncol.2018.4836. [Epub ahead of print]

PMID:
30452521
12.

Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes.

Pompe RS, Leyh-Bannurah SR, Preisser F, Salomon G, Graefen M, Huland H, Karakiewicz PI, Tilki D.

Urol Oncol. 2018 Dec;36(12):527.e21-527.e28. doi: 10.1016/j.urolonc.2018.08.010. Epub 2018 Nov 12.

PMID:
30442538
13.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.

PMID:
30430607
14.

North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients.

Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, Saad F, Soulières D, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Br J Cancer. 2018 Dec;119(12):1552-1556. doi: 10.1038/s41416-018-0323-3. Epub 2018 Nov 14.

PMID:
30425350
15.

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.

Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Jacobsen F, Huland H, Steurer S, Lebok P, Hinsch A, Wilczak W, Schlomm T, Simon R.

Oncol Lett. 2018 Nov;16(5):6238-6244. doi: 10.3892/ol.2018.9417. Epub 2018 Sep 7.

16.

Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis.

Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Saad F, Chun FK, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Int J Urol. 2018 Nov;25(11):929-936. doi: 10.1111/iju.13780. Epub 2018 Aug 26.

PMID:
30146729
17.

Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.

Preisser F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol. 2018 Dec;74(6):693-696. doi: 10.1016/j.eururo.2018.07.006. Epub 2018 Jul 20.

PMID:
30037529
18.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T.

Eur Urol. 2018 Sep;74(3):376-386. doi: 10.1016/j.eururo.2018.05.034. Epub 2018 Jun 13.

PMID:
29908878
19.

Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection.

Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Montorsi F, Saad F, Briganti A, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Urol Oncol. 2018 Aug;36(8):365.e1-365.e7. doi: 10.1016/j.urolonc.2018.05.019. Epub 2018 Jun 7.

PMID:
29887241
20.

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.

Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A.

BMC Cancer. 2018 May 31;18(1):612. doi: 10.1186/s12885-018-4547-7.

21.

Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database.

Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, Shariat SF, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2018 May 22. pii: S2405-4569(18)30123-8. doi: 10.1016/j.euf.2018.05.006. [Epub ahead of print]

PMID:
29802052
22.

Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems.

Pompe RS, Beyer B, Haese A, Preisser F, Michl U, Steuber T, Graefen M, Huland H, Karakiewicz PI, Tilki D.

BJU Int. 2018 Nov;122(5):801-807. doi: 10.1111/bju.14369. Epub 2018 Jun 4.

PMID:
29727912
23.

Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.

Pompe RS, Tilki D, Preisser F, Leyh-Bannurah SR, Bandini M, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, Shariat SF, Huland H, Graefen M, Briganti A, Karakiewicz PI.

Prostate. 2018 Jul;78(10):753-757. doi: 10.1002/pros.23519. Epub 2018 Apr 16.

PMID:
29663462
24.

The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy.

Tilki D, Preisser F, Karakiewicz P, Shariat SF, Graefen M, Huland H, Chun FK, Pompe RS.

World J Urol. 2018 Aug;36(8):1247-1253. doi: 10.1007/s00345-018-2274-y. Epub 2018 Mar 26.

PMID:
29582100
25.

Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.

Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, Graefen M, Huland H, Tian Z, Tilki D.

Prostate. 2018 Jun;78(9):676-681. doi: 10.1002/pros.23511. Epub 2018 Mar 23.

PMID:
29570821
26.

Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients.

Schiffmann J, Karakiewicz PI, Rink M, Manka L, Salomon G, Tilki D, Budäus L, Pompe R, Leyh-Bannurah SR, Haese A, Hammerer P, Huland H, Graefen M, Tennstedt P.

World J Urol. 2018 Jul;36(7):1067-1072. doi: 10.1007/s00345-018-2240-8. Epub 2018 Mar 2.

PMID:
29497861
27.

Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI.

Pompe RS, Kühn-Thomä B, Nagaraj Y, Veleva V, Preisser F, Leyh-Bannurah SR, Graefen M, Huland H, Tilki D, Salomon G.

World J Urol. 2018 May;36(5):705-712. doi: 10.1007/s00345-018-2238-2. Epub 2018 Feb 28.

PMID:
29492583
28.

Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram.

Pompe RS, Bandini M, Preisser F, Marchioni M, Zaffuto E, Tian Z, Salomon G, Schlomm T, Huland H, Graefen M, Tilki D, Shariat SF, Karakiewicz PI.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):386-393. doi: 10.1038/s41391-018-0033-1. Epub 2018 Feb 27.

PMID:
29487397
29.

Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.

Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, Shariat SF, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Prostate. 2018 May;78(6):469-475. doi: 10.1002/pros.23491. Epub 2018 Feb 19.

PMID:
29460290
30.

Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.

Pompe RS, Smith A, Bandini M, Marchioni M, Martel T, Preisser F, Leyh-Bannurah SR, Schiffmann J, Saad F, Huland H, Graefen M, Shariat SF, Tilki D, Karakiewicz PI.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):71-77. doi: 10.1038/s41391-017-0006-9. Epub 2018 Jan 16.

PMID:
29339806
31.

Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer.

Kluth M, Jung S, Habib O, Eshagzaiy M, Heinl A, Amschler N, Masser S, Mader M, Runte F, Barow P, Frogh S, Omari J, Möller-Koop C, Hube-Magg C, Weischenfeldt J, Korbel J, Steurer S, Krech T, Huland H, Graefen M, Minner S, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Nov 11;8(65):108923-108935. doi: 10.18632/oncotarget.22408. eCollection 2017 Dec 12.

32.

The Impact of Lymph Node Metastases Burden at Radical Prostatectomy.

Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Pompe RS, Montorsi F, Saad F, Abdollah F, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2018 Jan 3. pii: S2405-4569(17)30296-1. doi: 10.1016/j.euf.2017.12.009. [Epub ahead of print]

PMID:
29306731
33.

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.

Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A.

BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3.

34.

Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification.

Leyh-Bannurah SR, Budäus L, Zaffuto E, Pompe RS, Bandini M, Briganti A, Montorsi F, Schiffmann J, Shariat SF, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI.

Urol Oncol. 2018 Feb;36(2):81.e17-81.e24. doi: 10.1016/j.urolonc.2017.10.022. Epub 2017 Dec 14.

PMID:
29248430
35.

Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes.

Evans SM, Millar JL, Moore CM, Lewis JD, Huland H, Sampurno F, Connor SE, Villanti P, Litwin MS.

BMJ Open. 2017 Nov 28;7(11):e017006. doi: 10.1136/bmjopen-2017-017006.

36.

Radical prostatectomy in patients aged 75 years or older: review of the literature.

Mandel P, Chandrasekar T, Chun FK, Huland H, Tilki D.

Asian J Androl. 2017 Sep 26. doi: 10.4103/aja.aja_43_17. [Epub ahead of print] Review.

37.

Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy.

Leyh-Bannurah SR, Karakiewicz PI, Dell'Oglio P, Briganti A, Schiffmann J, Pompe RS, Sauter G, Schlomm T, Heinzer H, Huland H, Graefen M, Budäus L.

Clin Genitourin Cancer. 2017 Aug 31. pii: S1558-7673(17)30246-X. doi: 10.1016/j.clgc.2017.08.005. [Epub ahead of print]

PMID:
28942009
38.

Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center.

Pompe RS, Tian Z, Preisser F, Tennstedt P, Beyer B, Michl U, Graefen M, Huland H, Karakiewicz PI, Tilki D.

Eur Urol Focus. 2017 Dec;3(6):615-620. doi: 10.1016/j.euf.2017.08.001. Epub 2017 Aug 30.

PMID:
28869202
39.

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS, Simon R, Sauter G, Izbicki JR, Clauditz TS, Luebke AM, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N.

Neoplasia. 2017 Sep;19(9):707-715. doi: 10.1016/j.neo.2017.06.003. Epub 2017 Aug 19.

40.

Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Mandel P, Rosenbaum C, Pompe RS, Steuber T, Salomon G, Chun FK, Graefen M, Huland H, Tilki D.

World J Urol. 2017 Dec;35(12):1833-1839. doi: 10.1007/s00345-017-2079-4. Epub 2017 Aug 21.

PMID:
28828530
41.

Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.

Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G, Budäus L, Tilki D, Heinzer H, Graefen M, Mandel P.

Eur Urol Focus. 2017 Dec;3(6):646-649. doi: 10.1016/j.euf.2017.06.016. Epub 2017 Jul 8.

PMID:
28753877
42.

Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy.

Mandel P, Linnemannstöns A, Chun F, Schlomm T, Pompe R, Budäus L, Rosenbaum C, Ludwig T, Dahlem R, Fisch M, Graefen M, Huland H, Tilki D, Steuber T.

Eur Urol Focus. 2018 Jul;4(4):554-557. doi: 10.1016/j.euf.2017.01.008. Epub 2017 Feb 7.

PMID:
28753847
44.

Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.

Wallis CJD, Glaser A, Hu JC, Huland H, Lawrentschuk N, Moon D, Murphy DG, Nguyen PL, Resnick MJ, Nam RK.

Eur Urol. 2018 Jan;73(1):11-20. doi: 10.1016/j.eururo.2017.05.055. Epub 2017 Jun 11. Review.

PMID:
28610779
45.

Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.

Budäus L, Schiffmann J, Graefen M, Huland H, Tennstedt P, Siegmann A, Böhmer D, Budach V, Bartkowiak D, Wiegel T.

Strahlenther Onkol. 2017 Sep;193(9):692-699. doi: 10.1007/s00066-017-1140-y. Epub 2017 May 3.

PMID:
28470414
46.

Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.

Boehm K, Leyh-Bannurah SR, Rosenbaum C, Brandi LS, Budäus L, Graefen M, Huland H, Haferkamp A, Tilki D.

BJU Int. 2017 Nov;120(5):666-672. doi: 10.1111/bju.13887. Epub 2017 May 29.

47.

Local Therapy Improves Survival in Metastatic Prostate Cancer.

Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI.

Eur Urol. 2017 Jul;72(1):118-124. doi: 10.1016/j.eururo.2017.03.020. Epub 2017 Apr 3.

PMID:
28385454
48.

High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.

Steurer S, Rico SD, Simon R, Minner S, Tsourlakis MC, Krech T, Koop C, Graefen M, Heinzer H, Adam M, Huland H, Schlomm T, Sauter G, Lumiani A.

BJU Int. 2017 Sep;120(3):365-376. doi: 10.1111/bju.13840. Epub 2017 Apr 11.

49.

Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.

Pompe RS, Karakiewicz PI, Tian Z, Mandel P, Steuber T, Schlomm T, Salomon G, Graefen M, Huland H, Tilki D.

J Urol. 2017 Aug;198(2):354-361. doi: 10.1016/j.juro.2017.02.070. Epub 2017 Feb 16.

PMID:
28216329
50.

Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.

Schiffmann J, Salomon G, Tilki D, Budäus L, Karakiewicz PI, Leyh-Bannurah SR, Pompe RS, Haese A, Heinzer H, Huland H, Graefen M, Tennstedt P.

Urol Oncol. 2017 May;35(5):243-249. doi: 10.1016/j.urolonc.2016.12.014. Epub 2017 Feb 1.

PMID:
28161322

Supplemental Content

Loading ...
Support Center